ReviewFrontiers in immunology2022
Discovering Immune-Mediated Mechanisms of Gastric Carcinogenesis Through Single-Cell RNA Sequencing.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Bibliometric analysis: a study of the chronic atrophic gastritis in gastric cancer (2015-2024).Frontiers in oncology · 2025Pooled it
- Optimizing immunotherapy in advanced gastric cancer: established and emerging biomarkers for precision patient selection.Frontiers in immunology · 2026Review
- Single cell analysis reveals cancer associated fibroblast subtypes as prognostic markers and therapeutic targets in gastric cancer.Discover oncology · 2025Article
- Spatial transcriptome and single-cell sequencing reveal the role of nucleotide metabolism in breast cancer progression and tumor microenvironment.Frontiers in oncology · 2025Article
- Single-cell RNA sequencing to map tumor heterogeneity in gastric carcinogenesis paving roads to individualized therapy.Cancer immunology, immunotherapy : CII · 2024Review
- Spatial transcriptome and single-cell reveal the role of nucleotide metabolism in colorectal cancer progression and tumor microenvironment.Journal of translational medicine · 2024Article
- Exploring the current landscape of single-cell RNA sequencing applications in gastric cancer research.Journal of cellular and molecular medicine · 2024Review
- Unraveling the causal role of immune cells in gastrointestinal tract cancers: insights from a Mendelian randomization study.Frontiers in immunology · 2024Article
- Predictive Biomarkers for Immunotherapy in Gastric Cancer: Current Status and Emerging Prospects.International journal of molecular sciences · 2023Review
- Linking dysbiosis to precancerous stomach through inflammation: Deeper than and beyond imaging.Frontiers in immunology · 2023Review
- Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Single-cell RNA sequencing (scRNAseq) technology is still relatively new in the field of gastric cancer immunology but gaining significant traction. This technology now provides unprecedented insights into the intratumoral and intertumoral heterogeneities at the immunological, cellular, and molecular levels. Within the last few years, a volume of publications reported the usefulness of scRNAseq technology in identifying thus far elusive immunological mechanisms that may promote and impede gastric cancer development. These studies analyzed datasets generated from primary human gastric cancer tissues, metastatic ascites fluid from gastric cancer patients, and laboratory-generated data from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.